Advertisement

Topics

Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 67-page report is available in PDF from $2000.

Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015’, provides an overview of the Resistant Pseudomonas Aeruginosa Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Resistant Pseudomonas Aeruginosa Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Resistant Pseudomonas Aeruginosa Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Resistant Pseudomonas Aeruginosa Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Resistant Pseudomonas Aeruginosa Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Resistant Pseudomonas Aeruginosa Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Resistant Pseudomonas Aeruginosa Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Resistant Pseudomonas Aeruginosa Infections Overview 8
Therapeutics Development 9
Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Overview 9
Pipeline Products for Resistant Pseudomonas Aeruginosa Infections - Comparative Analysis 10
Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Development by Companies 11
Resistant Pseudomonas Aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 12
Resistant Pseudomonas Aeruginosa Infections - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Resistant Pseudomonas Aeruginosa Infections - Products under Development by Companies 15
Resistant Pseudomonas Aeruginosa Infections - Products under Investigation by Universities/Institutes 16
Resistant Pseudomonas Aeruginosa Infections - Companies Involved in Therapeutics Development 17
Achaogen Inc. 17
AstraZeneca PLC 18
Biolytics Pharma 19
CSA Biotechnologies LLC 20
LegoChem Biosciences, Inc 21
Melinta Therapeutics, Inc 22
Microbion Corporation 23
Phico Therapeutics Ltd. 24
Phylogica Limited 25
Shionogi & Co., Ltd. 26
Zambon Company S.p.A. 27
Resistant Pseudomonas Aeruginosa Infections - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
ACHN-975 Prodrug - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Biologic for Pseudomonas Aeruginosa Infection - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cephalosporin + Beta-Lactamase Inhibitor - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CSA-13 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
G-10 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
LCB-100200 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
PT-3.33 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
RXP-763 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
RXP-766 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
RXP-770 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RXP-792 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
RXP-793 - Drug Profile 53
Product Description 53
Mechanism of Action 53
For more information open Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015.

SKU: GMDHC6621IDB

Original Article: Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Resistant Pseudomonas Aeruginosa Infections - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...